CoChat

Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector

The DOI matches its Crossref record, with a small difference in title or year; 336 of the 336 references it cites were found in a registry or an index.

Abstract

Prévention et inhibition de la réponse immune humorale indésirable à la thérapie génique médiée par le vecteur viral adéno-associés (AAV) La thérapie génique peut être définie comme le transfert du gène thérapeutique dans le tissue d’intérêt à l’aide d’un vecteur. A ce jour, les vecteurs dérivés du virus adéno-associés (AAV) représentent les vecteurs de choix pour le transfert de gène in vivo. Cependant, les réponses immunitaires dirigées contre la capside AAV représentent l’obstacle majeur à l’efficacité du transfert de gène médié par le vecteur AAV. Ce travail de thèse a eu pour objectifs de prévenir et d’inhiber la réponse humorale dirigée contre le vecteur AAV. En administrant des nanoparticules contenant de la rapamycine (ou SVP[Rapa]) avec le vecteur AAV, nous avons démontré une inhibition spécifique des réponses humorale et cellulaire dirigées contre la capside AAV. De plus, cette stratégie nous a permis de re-administrer efficacement le vecteur AAV dans des modèles murins et chez le singe. Nos données ont aussi démontré l’élimination des anticorps préexistants dirigés contre le vecteur AAV en administrant SVP[Rapa] avec le bortezomib. Au cours de travail de thèse, nous avons aussi développée et testée l’efficacité des vecteurs AAV associés aux vésicules extracellulaires (vecteurs exo-AAV) à améliorer l’efficacité des vecteurs AAV. En utilisant les vecteurs exo-AAV, nous avons démontré une expression stable et durable du transgène. De plus, les vecteurs exo-AAV ont montré une résistance aux anticorps neutralisants préexistants. Ainsi, au cours de ce projet de thèse des stratégies efficaces ont été développées afin de prévenir et de contrôler les réponses immunitaires dirigés contre le vecteur AAV, permettant ainsi une re-administration efficace du vecteur AAV.

Overview

Integrity signals

Registry

Crossref · 10.70675/83ee599czfe90z44e6za201z0938409e1748

Cites

336 of 336 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 336 references

Research works printed but not linked: 17

  1. Masat Elisa, Pavani Giulia, Mingozzi Federico, Humoral Immunity to AAV Vectors in Gene Therapy: Challenges and Potential Solutions., in: Discovery Medicine, vol. 15, n° (85), p. 379-89, 2013, http://www.ncbi.nlm.nih.gov/pubmed/23819952
  2. Nathwani A. C., Adeno-associated virus vector-mediated gene transfer of factor IX gene therapy in hemophilia B, in: N Engl J Med., vol. 365, p. 2357-2365, 2011
  3. Neelapu Sattva S., Locke Frederick L., Bartlett Nancy L., Lekakis Lazaros J., Miklos David B., Jacobson Caron A., Braunschweig Ira, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma., in: New England Journal of Medicine, 2017, 10.1056/NEJMoa1707447 · DOI · Paper page
  4. Berns K. I., Giraud C., Biology of Adeno-Associated Virus, p. 1–23, Springer, Berlin, Heidelberg, 1996, 10.1007/978-3-642-80207-2_1 · DOI · Paper page
  5. Rayaprolu Vamseedhar, Kruse Shannon, Kant Ravi, Venkatakrishnan Balasubramanian, Movahed Navid, Brooke Dewey, Lins Bridget, Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics, in: Journal of Virology, vol. 87, n° 24, p. 13150-60, American Society for Microbiology (ASM), 2013, 10.1128/JVI.01415-13 · DOI · Paper page
  6. Larson J E, Cohen J C, In Utero Gene Therapy., in: The Ochsner Journal, vol. 2, n° 2, p. 107-10, Ochsner Clinic, L.L.C. and Alton Ochsner Medical Foundation, 2000, http://www.ncbi.nlm.nih.gov/pubmed/21765673
  7. Methods in Molecular Biology 807, 2008, 10.1007/978-1-61779-370-7_1 · DOI · Paper page
  8. Morrow Thomas, Novartis's Kymriah: Harnessing Immune System Comes With Worry About Reining in Costs., in: Managed Care (Langhorne, Pa.), vol. 26, n° 10, p. 28-30, 2017, http://www.ncbi.nlm.nih.gov/pubmed/29068298
  9. Wang Dan, Gao Guangping, State-of-the-Art Human Gene Therapy: Part I. Gene Delivery Technologies., in: Discovery Medicine, vol. 18, n° (97), p. 67-77, 2014, http://www.ncbi.nlm.nih.gov/pubmed/25091489
  10. Wang Dan, Gao Guangping, State-of-the-Art Human Gene Therapy: Part II. Gene Therapy Strategies and Clinical Applications., in: Discovery Medicine, vol. 18, n° (98), p. 151-61, 2014, http://www.ncbi.nlm.nih.gov/pubmed/25227756
  11. Janeway Charles.A, Travers Paul, Walport Mark, Shlomchik Mark.J, The Complement System and Innate Immunity., Garland Science, 2001, https://www.ncbi.nlm.nih.gov/books/NBK27100/.
  12. Janeway Charles.A, The Structure of a Typical Antibody Molecule., Garland Science, 2001, https://www.ncbi.nlm.nih.gov/books/NBK27144/.
  13. Armant Myriam. A, Fenton Matthew. J, Toll-like Receptors: A Family of Pattern-Recognition Receptors in Mammals., in: Genome Biology, vol. 3, n° 8, BioMed Central, 2002, http://www.ncbi.nlm.nih.gov/pubmed/12186654
  14. Herzog Roland W, Cao Ou, Srivastava Arun, Two Decades of Clinical Gene Therapy--Success Is Finally Mounting., in: Discovery Medicine, vol. 9, n° 45, p. 105-11, 2010, http://www.ncbi.nlm.nih.gov/pubmed/20193635
  15. Fiorentino David F., Bond Martha W., Mosman Tim R., Mosmann Tim R., TWO TYPES OF MOUSE T HELPER CELL IV. Th2 Clones Secrete a Factor That Inhibits Cytokine Production by Th1 Clones., 2017, https://pdfs.semanticscholar.org/020d/72677a2c25c0159d6c3ab81a11c231161e66.pdf
  16. TYPES OF MOUSE T HELPER CELL IV. Th2 Clones Secrete a Factor That Inhibits Cytokine Production by Thl Clones., https://pdfs.semanticscholar.org/020d/72677a2c25c0159d6c3ab81a11c231161e66.pdf
  17. American Association of Immunologists, with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis., in: Journal of Immunology, vol. 186, n° (4), p. 2503-13, Baltimore, Md.: 1950, 2010, 10.4049/jimmunol.1002539 · DOI · Paper page

Metadata

Authors
Meliani, A.
Affiliations
Sorbonne Université (FR)
Corresponding author
Meliani, Amine
Published
2018-01-24
OpenAlex
W7148714555
Cited by
0
References
335
Type
dissertation
Language
fr
Open access
closed
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
adeno-associated virus vectors, humoral immune response, rapamycin, bortezomib, exosomes, neutralizing antibodies, transgene expression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector. https://app.cochat.ai/papers/10.70675/83ee599czfe90z44e6za201z0938409e1748
The paper
Meliani, A. (2026). Prevention and inhibition of adverse humoral immune response to gene therapy mediated by adeno-associated virus (AAV) vector. https://doi.org/10.70675/83ee599czfe90z44e6za201z0938409e1748

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.